EVMN NYSE
Evommune, Inc.
1W: -4.7%
1M: -38.9%
3M: -53.6%
YTD: -70.4%
$5.16
+0.03 (+0.58%)
Pre-Market: $5.41 (+0.25, +4.84%)
Weekly Expected Move ±9.6%
$4
$5
$5
$6
$6
Credit Risk of going bust: higher than 76% of companies Debt: 4.2% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the third-riskiest tenth, about 1 in 140 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.05 (down 99.1%), Evommune, Inc. would be worth roughly what it owes.
Total debt $8.1M against a stock market value of $187.3M.
Distance to default 2.94 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $4.1M (short-term plus half of long-term), stock volatility 113.7%; Altman Z'' 10.89. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.05 (down 99.1%), Evommune, Inc. would be worth roughly what it owes.
Total debt $8.1M against a stock market value of $187.3M.
Distance to default 2.94 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $4.1M (short-term plus half of long-term), stock volatility 113.7%; Altman Z'' 10.89. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$187.3M
52W Range4.94-33.2
Volume1,301,850
Avg Volume842,699
Beta0.96
Dividend—
Analyst Ratings
Company Info
CEOLuis C. Pena
Employees48
SectorHealthcare
IndustryBiotechnology
IPO Date2025-11-06
Websiteevommune.com
1841 Page Mill Road
Palo Alto, CA 94304
US
Palo Alto, CA 94304
US
(925) 247-4487
About Evommune, Inc.
Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.
Latest News
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Pena Luis C. | A-Award | 1,115 | $7.02 | 2026-09-30 |